




RealRate

PHARMACEUTICAL 2022

AILERON THERAPEUTICS INC
Rank 323 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2022

AILERON THERAPEUTICS INC Rank 323 of 475

The relative strengths and weaknesses of AILERON THERAPEUTICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AILERON THERAPEUTICS INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 156% points. The greatest weakness of AILERON THERAPEUTICS INC is the variable Net Income, reducing the Economic Capital Ratio by 158% points.

The company's Economic Capital Ratio, given in the ranking table, is -218%, being 58% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	48,177
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,508
Liabilities, Non-Current	69
Other Assets	176
Other Compr. Net Income	-11
Other Expenses	0
Other Liabilities	0
Other Net Income	441
Property and Equipment	128
Research and Development	17,008
Revenues	0
Selling, General and Administrative Expense	9,597

Output Variable	Value in 1000 USD
Assets	48,481
Liabilities	4,577
Expenses	26,605
Stockholders Equity	43,904
Net Income	-26,164
Comprehensive Net Income	-26,170
Economic Capital Ratio	-218%

